DOCSLIB.ORG

Download Article

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Article ] ] [ News ] Analysis ] Commentary ] Controversy ] June 25, 2012 Vol. 34 No. 12 oncology-times.com Publishing for O34 Years NCOLOGY The Independent IMES Hem/Onc News Source T ASCO Annual Meeting! • Controlling Breakthrough Chemo-Induced Nausea & Vomiting • Needed: More MD Knowledge about Long-Term Effects of Cancer Drugs • Myeloma: Novel Agents + Standard Therapy for Bortezomib-Refractory Patients • CLL: Ibrutinib for Older Patients • GIST: New Third-Line Agent • Pediatric Cancer: Crizotinib Effective for ALK-Driven Tumors Coverage starts on page 8 Photos from the Annual Meeting: Todd Buchanan/ASCO2012 Todd Meeting: the Annual from Photos Hodgkin Lymphoma: ANNE TSAO: How I Treat Novel Agents as Bridge Changing Perceptions about Patients with Limited-Stage to Transplant for Selected Unnecessary Tests p.9 OT iPad App! Small Cell Lung Cancer p.20 Patients p.26 [ALSO] SHOP TALK �� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �5 LETTERS� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �6 Crossover Trial Validates Accelerated Approval of Sunitinib for GIST � � � � � � � � � � � � � � � � � � � � � �19 Early Breast Cancer: HER2 Peptide Vaccine Helps Delay Recurrence � � � � � � � � � � � � � � � � � � � � � �24 GEORGE SLEDGE: ‘Perchance to Dream’ �� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �28 POETRY BY CANCER CAREGIVERS: Amir Steinberg, MD �� � � � � � � � � � � � � � � � � � � � � � � � � �30 Treating Hepatitis Infection and Liver Cancer Together �� � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � �30 Facebook.com/ @OncologyTimes PERIODICALS OncologyTimesNews B:10.75” T:10.5” S:9.5” 5 TARCEVA® (erlotinib) TABLETS BRIEF SUMMARY Please see including abnormal eyelash growth, keratoconjunctivitis sicca or keratitis elevations were mainly transient or associated with liver metastases. pustules, but is histopathologically different. This skin reaction commonly the Tarceva package insert for full prescribing information. have been observed with TARCEVA treatment and are known risk factors Grade 2 (> 2.5 – 5.0 x ULN) ALT elevations occurred in 4% and <1% of occurs on the face, upper chest and back, but may be more generalized or Appointments, Promotions, Honors, oncology times INDICATIONS AND USAGE Non-Small Cell Lung Cancer for corneal ulceration/perforation [see Adverse Reactions (6.1)]. Interrupt TARCEVA and placebo treated patients, respectively. Grade 3 (> 5.0 – 20.0 severe (NCI-CTC Grade 3 or 4) with desquamation. Skin reactions may Grants, & ‘People News’ (NSCLC) TARCEVA monotherapy is indicated for the maintenance or discontinue TARCEVA therapy if patients present with acute/worsening x ULN) elevations were not observed in TARCEVA-treated patients. occur or worsen in sun exposed areas; therefore, the use of sunscreen or Shop Talk treatment of patients with locally advanced or metastatic non-small cell ocular disorders such as eye pain. Elevated International TARCEVA dosing should be interrupted or discontinued if changes in liver avoidance of sun exposure is recommended. Associated symptoms may lung cancer whose disease has not progressed after four cycles of Normalized Ratio and Potential Bleeding International Normalized function are severe [see Dosage and Administration (2.3)]. Pancreatic include itching, tenderness and/or burning. Also, hyperpigmentation or platinum-based first-line chemotherapy [see Clinical Studies (14.1)]. Ratio (INR) elevations and bleeding events, including gastrointestinal and Cancer Adverse reactions, regardless of causality, that occurred in at dry skin with or without digital skin fissures may occur. Hair and nail TARCEVA monotherapy is indicated for the treatment of patients with non-gastrointestinal bleeding (including fatalities), have been associated least 10% of patients treated with TARCEVA 100 mg plus gemcitabine in disorders including alopecia, hirsutism, eyelash/eyebrow (see above) locally advanced or metastatic non-small cell lung cancer after failure of with concomitant warfarin administration. Patients taking warfarin or other the randomized trial of patients with pancreatic cancer are summarized by changes, paronychia and brittle and loose nails have been reported. at least one prior chemotherapy regimen [see Clinical Studies (14.2)]. coumarin-derivative anticoagulants should be monitored regularly for NCI-CTC (version 2.0) Grade in Table 3. The most common adverse Other Disorders Epistaxis was also reported in both the single-agent Results from two, multicenter, placebo-controlled, randomized, Phase 3 changes in prothrombin time or INR [see Adverse Reactions (6.1) and reactions in pancreatic cancer patients receiving TARCEVA 100 mg plus NSCLC and the pancreatic cancer clinical trials. In general, no notable At Moffitt Cancer The Academy of Medical Sciences of Maureen T. Kavanah, Research Program at Yale Cancer Center trials conducted in first-line patients with locally advanced or metastatic Drug Interactions (7)]. Use in Pregnancy TARCEVA can cause fetal gemcitabine were fatigue, rash, nausea, anorexia and diarrhea. In the differences in the safety of TARCEVA monotherapy or in combination with Center, G. Douglas the UK has elected 46 medical research- MD, Associate Pro- and Smilow Cancer Hospital at Yale- NSCLC showed no clinical benefit with the concurrent administration of harm when administered to a pregnant woman. Erlotinib administered to TARCEVA plus gemcitabine arm, Grade 3/4 rash and diarrhea were each gemcitabine could be discerned between females or males and between TARCEVA with platinum-based chemotherapy [carboplatin and paclitaxel rabbits during organogenesis at doses that result in plasma drug reported in 5% of TARCEVA plus gemcitabine-treated patients. The patients younger or older than the age of 65 years [see Use in Specific Letson, MD, has been ers to the Fellowship of the Academy fessor of Surgery at New Haven Hospital, a change that will • or gemcitabine and cisplatin] and its use is not recommended in that concentrations of approximately 3 times those in humans at the Populations (8.5 and 8.6)]. The safety of TARCEVA appears similar in median time to onset of rash and diarrhea was 10 days and 15 days, appointed Executive of Medical Sciences. “These new Boston University take effect in August. june 25, 2012 setting [see Clinical Studies (14.3)]. Pancreatic Cancer TARCEVA in recommended dose of 150 mg daily, was associated with embryofetal respectively. Rash and diarrhea each resulted in dose reductions in 2% of Caucasian and Asian patients. Post-marketing Experience The combination with gemcitabine is indicated for the first-line treatment of lethality and abortion. When erlotinib was administered to female rats patients, and resulted in study discontinuation in up to 1% of patients following adverse reactions have been identified during post approval use Vice President for Fellows represent the wealth of talent School of Medicine and patients with locally advanced, unresectable or metastatic pancreatic prior to mating and through the first week of pregnancy, at doses 0.3 or receiving TARCEVA plus gemcitabine. The 150 mg cohort was associated of TARCEVA. Because these reactions are reported voluntarily from a Clinical Affairs and within the UK biomedical commu- Surgical Oncologist at Eward C. Halperin, 2 cancer [see Clinical Studies (14.4)]. CONTRAINDICATIONS None. 0.7 times the clinical dose of 150 mg, on a mg/m basis, there was an with a higher rate of certain class-specific adverse reactions including population of uncertain size, it is not always possible to reliably estimate Physician-in-Chief, and nity,” said Professor Sir John Tooke, Boston Medical Center MD, MA, has become WARNINGS AND PRECAUTIONS Pulmonary Toxicity There have increase in early resorptions that resulted in a decrease in the number of rash and required more frequent dose reduction or interruption. Table 3: their frequency or establish a causal relationship to drug exposure. Skin G. DOUGLAS KATHY been reports of serious Interstitial Lung Disease (ILD)-like events, live fetuses [see Use in Specific Populations (8.1)]. There are no adequate Adverse Reactions Occurring in ≥ 10% of TARCEVA-treated and subcutaneous tissue disorders Hair and nail changes, mostly Johnathan Lancaster, PMedSci, President of the Academy of (BMC), has received Chancellor for Health including fatalities, in patients receiving TARCEVA for treatment of NSCLC, and well-controlled studies in pregnant women using TARCEVA. Women Pancreatic Cancer Patients: 100 mg cohort non-serious e.g. hirsutism, eyelash/eyebrow changes, paronychia and MD, PhD, has been ap- LETSON, MD Medical Sciences, in a news release. The the 2012 National PRITCHARD- Affairs and Chief pancreatic cancer or other advanced solid tumors. In the randomized of childbearing potential should be advised to avoid pregnancy while on TARCEVA + Placebo + brittle and loose nails. Bullous, blistering and exfoliative skin conditions JONES, single-agent NSCLC studies [see Clinical Studies (14.1, 14.2)], the TARCEVA. Adequate contraceptive methods should be used during Gemcitabine Gemcitabine have been reported including cases suggestive of Stevens-Johnson pointed President of the new fellows include Surgical Adjuvant Executive Officer at New 1000 mg/m2 IV 1000 mg/m2 IV FMEDSCI incidence of serious ILD-like events in the TARCEVA treated patients versus therapy, and for at least 2 weeks after completing
Load more

Recommended publications
  • Las Vegas, Nevada
    TIM TO THRIVE PROMOTING SAFETY, INCLUSION AND WELL-BEING FOR LGBTQ YOUTH…EVERYWHERE! FEBRUARY 14 – 16, 2014 LAS VEGAS, NEVADA PRESENTING SPONSOR: CO-PRESENTING CONFERENCE PARTNERS: BALLY’S LAS VEGAS 26TH FLOOR BALLY’S EVENT CENTER • Plenaries • Conference Meals Office • Exhibitors CONFERENCE Skyview 4 REGISTRATION Skyview 3 Conference Room Skyview 2 omenade r Bally’s P Catering & w e Convention i v Sales y Skyview 1 k S PALACE MEETING ROOMS J Elevators ELEVATORS TO WORKSHOPS HELD IN Drai's Skyview SKYVIEW ROOMS 1-6 Foyer Les (GO TO FLOOR 26) Elements Signatures Gift Shop Burger Brasserie The Strip Digital Skyview 5 World Skyview 6 CASINO LEVEL ELEVATORS TO WORKSHOPS HELD IN LAS VEGAS 1-7 (GO TO FLOOR 3) 1 2 3 4 5 6 7 Lobby Offices LAS VEGAS BALLROOM s r Convention o Service Office at v e l E THIRD FLOOR WELCOME Thank you for attending the Human Rights Campaign Foundation’s inaugural national conference, Time to THRIVE, co-presented by the National Education Association and the American Counseling Association. We have three exciting and empowering days planned to help you promote safety, inclusion and well-being for LGBTQ youth in your community. This conference would not be possible without support from our sponsors, including a generous presenting sponsorship from AT&T. This weekend you will hear from amazing speakers, special guests and expert presenters in dozens of workshops. Our goal in all of this is to give you answers and resources that help you do important work in your own communities. In my work with the Human Rights Campaign Foundation and as a former educator, I know first-hand that being a change agent takes courage and intentionality.
    [Show full text]
  • Distinguished World Leaders in Science and Technology Mentoring
    Distinguished World Leaders in Aneesh Chopra Sylvester James Gates, Jr., Ph.D. Chief Technology Officer of the United States, 2009-2012 Recipient, National Medal of Science for Physical Science Science and Technology Mentoring Aneesh Chopra is a groundbreaking member of the technology Dr. Gates is one of America’s most renowned theoretical physicists. field. Appointed by President Barack Obama, he served as the first In 2013, he was elected to the National Academy of Sciences Chief Technology Officer of the United States. During his time in and became the first African-American physicist so recognized office, Aneesh designed the National Wireless Initiative, helped in its 150- year history. He is especially known for his work on Delegates Have Included... launch Startup America, and executed an “open innovation” strategy supersymmetry, supergravity, and superstring theory. Dr. Gates is currently a across the government. He is the author of the book, “Innovative State: How New Professor of Physics at Brown University; the Director of the String and Particle Technologies Can Transform Government.” Theory Center, and Affiliate Professor of Mathematics. He serves on the U.S. J. Craig Venter, Ph.D. President’s Council of Advisers on Science and Technology, on the National Commission on Forensic Science, and on the Maryland State Board of Education. — THE GRANDg MASTERS — Decoded the Human Genome Recipient, 2009 Presidential National Medal of Science Dean Kamen Dr. Venter is regarded as one of the leading scientists of the 21st Recipient, National Medal of Technology and Innovation John C. Mather, Ph.D. Legendary Inventor Academy Science Director century for his numerous contributions to genomic research.
    [Show full text]
  • Standup Walker of the Year NOMINATE YOUR RISING STAR in the HOME HEALTHCARE INDUSTRY FAVORITE INNOVATOR
    DIGEST InventorsAPRIL 2016 Volume 32 Issue 4 DIGEST IPOEF Inventor StandUp Walker of the Year NOMINATE YOUR RISING STAR IN THE HOME HEALTHCARE INDUSTRY FAVORITE INNOVATOR Jack Andraka DISCOVERS A DEVICE TO DETECT PANCREATIC CANCER Total Tie Keep NO MORE BLOWIN’ IN THE WIND 3D Printers ARE THEY WORTH THE INVESTMENT? Almost Perfect PROFITING FROM YOUR INVENTION The Business of Inventing DO YOU HAVE WHAT IT TAKES? $3.95 FULTON, MO FULTON, PERMIT 38 PERMIT US POSTAGE PAID POSTAGE US PRSRT STANDARD PRSRT EDITOR’S NOTE InventorsDIGEST The Next EDITOR-IN-CHIEF BIG Thing CAMA MCNAMARA This month’s cover story should be of interest to ART DIRECTOR inventors looking for the next big thing. While CARRIE BOYD over the past decade numerous products have been developed for tech-savvy, time-conscious CONTRIBUTORS millenials, at the opposite end of the spectrum STEPHEN BRACHMANN are aging baby boomers, who are creating INNOVATOR INSIGHTS multiple marketing opportunities. As their numbers continue to increase, so JACK LANDER does the potential for product development. JEREMY LOSAW Ken Paulus’ company, URise Products, is on the cutting-edge of what has GENE QUINN been coined the “silver tsunami.” According to the Pew Research Center, 10,000 JOHN RAU boomers will turn 65 today, and 10,000 more will turn 65 every day for the next 19 EDIE TOLCHIN years. That’s a lot of knees and hips in need of repair. It’s also an enormous number LAWRENCE J. UDELL of people searching for ways to maintain their health, mobility, independence and quality of life, which is of concern to Paulus and his company.
    [Show full text]
  • 2018 MACUL Conference Program
    Thank You MACUL 2018 Sponsors Platinum Gold Silver Bronze Event Table of Contents Welcome to MACUL 2018 .................................................................................2 Conference App ..............................................................................................3 Conference at a Glance ....................................................................................4 Conference Highlights .....................................................................................5 Conference Information ..................................................................................6 SCECHs ...........................................................................................................7 MACUL 2018 Award Winners ............................................................................8 MACUL Board of Directors, Staff, and SIG Directors ..........................................10 MACUL Conference Planning Committees .......................................................11 MACUL Past Presidents ..................................................................................12 MACUL Special Interest Group (SIG) Annual Meetings ......................................13 Session Styles ...............................................................................................14 Keynote Speakers .........................................................................................15 Featured Speakers ........................................................................................16
    [Show full text]
  • Attaining Energy, Water, and Food Security for All 14Th DELHI SUSTAINABLE DEVELOPMENT SUMMIT 5–8 February 2014 I New Delhi, India
    DSDS 2014 Attaining Energy, Water, and Food Security For All 14th DELHI SUSTAINABLE DEVELOPMENT SUMMIT 5–8 February 2014 I New Delhi, India PROCEEDINGS Contents Preface Acknowledgements .......................................................................................6 Attaining Energy, Water, and Food Security for All: A Background Note ........8 Agenda ........................................................................................................12 Prime Minister’s Message ............................................................................21 Keynote Addresses .....................................................................................23 Plenaries/ Launches/ Special Sessions .......................................................45 Leadership Panel I .......................................................................................46 Ministerial Session I ......................................................................................50 Ministerial Session II ...................................................................................104 Valedictory Session ....................................................................................124 Thematic Tracks .........................................................................................131 Exhibition....................................................................................................190 High Level Corporate Dialogue Proceedings ............................................192 Preface The experience, knowledge,
    [Show full text]
  • TITANS of PROSTATE CANCER Ment Is for Men Who Are Diagnosed with High-Grade Prostate Cancers That Are Likely Following the Johns Hopkins Model, Leaders in to Recur
    PROMISE& PROGRESS THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTE R AT JOHNS HOPKINS TRANSFORMIN G PROS TA TE CANCER DETECTION, DIAGNOSIS, AND TREATMENT 2012/2013 PROMISE&PROGR ESS 2012/2013 VOLUME ONE Promise & Progress is published by The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 06 Office of Public Affairs 901 South Bond Street Suite 573 Baltimore, Maryland 21231 (410) 955-1287 William G. Nelson, M.D., Ph.D. Director Amy Mone Director of Public Affairs Valerie Matthews Mehl Editor and Sr. Writer [email protected] Michelle Potter Production Manager and Editorial Assistant Vanessa Wasta Associate Director, Media Relations and Web Projects Keith Weller Feature Photography Peter Howard Cover Photography MSK Partners, Inc. Design and Production Printed in the USA CONTENTS ON THE WEB CONNECT WITH US 34 WWW.HOPKINSKIMMELCANCERCENTER.ORG 02 40 CANCER MATTERS , OUR BLOG FEATURING Headline Makers In The News Philanthropy TOPICS FROM CLINICIANS, RESEARCHERS, The latest research from Noteworthy progress, Gifts and donations that PATIENTS, AND STAFF. the Kimmel Cancer Center new appointments, and are funding our cancer including new discoveries other cancer news. research and advancing CANCER NEWS REVIEW , MONTHLY PODCAST in cancer treatments and clinical care. FROM DIRECTOR WILLIAM NELSON half-matched transplants MEDIA CENTER , VIDEO AND PODCAST GALLERY that may cure sickle cell disease. P&P PROMISE & PROGRESS WEB EXCLUSIVES On the Cover: Former Temptations singer Damon Harris, at his Owings Mills home. @HOPKINSMEDNEWS For additional copies of this publication or further information about the SEARCH FOR JOHNS HOPKINS MEDICINE Kimmel Cancer Center, please call (410) 955-1287 or email [email protected] © 2012 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins DIRECTOR’S LETTER REDEFINING CANCER THE KIMMEL CANCER Center is an treatment is delivered with evidence-base d, incredible cancer discovery engine.
    [Show full text]
  • Administration of Barack Obama, 2013 Remarks at the White House
    Administration of Barack Obama, 2013 Remarks at the White House Science Fair April 22, 2013 Thank you, everybody. Please have a seat. Have a seat. Well, good afternoon, everybody. And welcome to the White House science fair, one of my favorite events during the course of the year. And I just had a chance to see some of the outstanding exhibits that have been put forward by some of these amazing young people. And let me just start by saying, in my official capacity as President: This stuff is really cool. [Laughter] And I want to thank these incredible young people for explaining to me what the heck is going on. [Laughter] Every one of you is enormously talented, obviously, but there's also a community of people who helped all these young people succeed: dedicated teachers who believed in them and challenged them to do even more; all of them have loving parents and mentors and family. So I want to not only give the young people a big round of applause, but all the parents and teachers and principals and everybody who was involved, give yourselves a big round of applause as well. Of course, primarily, we're here to celebrate these young scientists and visionaries who dream and create and innovate, who ask the question, why not? Why not try something better, something that's faster, something that helps more people? And that drive, that refusal to give up, that focus on the future is part of what makes America great. And all of you are participants in this long line of inventors and creators that have made this the most dynamic economy and the most dynamic country on Earth.
    [Show full text]
  • 2015 Annual Report
    Redefining the Cancer Experience 2015 Annual Report 07337A.indd 1 8/9/16 5:35 PM ABOUT THE CANCER SUPPORT COMMUNITY As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC) is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action and sustained by community. CSC achieves its mission through three areas: direct service delivery, research and advocacy. The organization includes an international network of Affiliates that offer the highest quality social and emotional support for people impacted by cancer, as well as a community of support available online and over the phone. The Research and Training Institute conducts cutting-edge psychosocial, behavioral and survivorship research. CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington D.C. and across the nation. For more information, please call 1-888-793-9355, or visit CancerSupportCommunity.org. So that no one faces cancer alone.® TABLE OF CONTENTS By the Numbers .................. 4 Redefining the Cancer Experience Through Research ......................6 Support ...................... 8 Education .....................12 Advocacy......................14 Community ....................18 Thank You ...................... 22 Financial Report ................. 27 07337A.indd 2 8/9/16 5:35 PM Dear Friends of the Cancer Support Community, Thank you for your allowing us to be part of your journey, for your continued support and most of all, for your dedication to redefining the cancer experience. 2015 was a landmark year for the Cancer Support Community—a year in which we as an organization saw tremendous growth, and we as a community saw tremendous change in the cancer experience.
    [Show full text]
  • Complete Table of Contents
    | 6 Contents Foreword 11 Preface 13 Survey Results 17 Viewpoints 29 A Young Medical Innovator Looks Forward Jack Andraka 30 “Big Data” Boosts Healthcare Innovation Anil Jain, M.D. and Charlie Lougheed 37 The Importance of Basic Research Paul DiCorleto, Ph.D. 42 The Paper Chase: The Unending Scramble for Investment Dollars Patrick Fortune, Ph.D., M.B.A. 46 Riding the Gray Horse: Challenges of Being a Clinician-Entrepreneur Joseph Foss, M.D. 52 Driving Innovation for the Right Reasons Tom Gentile, M.B.A. 57 The Challenges Facing Medical Device Companies Frank Papay, M.D. 64 Making Industry-Academia Relationships Work D. Geoffrey Vince, Ph.D. 70 The Paradigm Shift in American Innovation Thomas Graham, M.D. 77 MEDICAL INNOVATION PLAYBOOK CONTENTS | 7 Institution Profiles 83 University of Alabama at Birmingham 84 By the Numbers 90 University of Arizona 91 By the Numbers 97 Beth Israel Deaconess Medical Center 98 By the Numbers 103 Boston Children’s Hospital 105 By the Numbers 111 Boston University 113 By the Numbers 118 University of California, Davis 119 By the Numbers 126 University of California, Irvine 127 By the Numbers 133 University of California, San Diego 134 By the Numbers 140 Case Western Reserve University 141 By the Numbers 147 Children’s Hospital of Philadelphia 148 By the Numbers 154 University of Cincinnati 155 By the Numbers 160 Cincinnati Children’s Hospital Medical Center 161 By the Numbers 167 Clemson University 169 By the Numbers 174 Cleveland Clinic 176 By the Numbers 183 University of Colorado 184 By the Numbers 190
    [Show full text]
  • Medical News the Teenage Scientist Revolutionizing Cancer Detection Medical Jokes
    Bangladesh Med J. 2013 May; 42 (2) Medical News The teenage scientist revolutionizing cancer detection Jack Andraka, from Crownsville, Maryland, USA was the pancreatic cancer. The test is over 90 percent accurate in recipient, at the age of 15, of the 2012 Gordon E. Moore detecting the presence of mesothelin. According to Award that worth $75000 , the grand prize of the Intel Andraka, it is also 168 times faster, 26,000 times less International Science and Engineering Fair and is being expensive (costing around three cents), over 400 times introduced as an young inventor, scientist and cancer more sensitive than the current diagnostic tests and only researcher for his ground breaking invention of early takes five minutes to run. He says the test is also effective detection of pancreatic cancer. for detecting ovarian and lung cancer, due to the same mesothelin biomarker they have in common. He was an average but very curious boy who enjoyed mountain biking, whitewater rafting, kayaking, and science Andraka cultured MIA PaCa cells, from a commercial until his uncle died of pancreatic cancer. The overall pancreatic carcinoma cell line, which overexpress survival of this malignancy is only 3-5% with median mesothelin, a biomarker for pancreatic cancer. The survival of 6-10 months for those with locally advanced mesothelin was isolated, concentrated and quantified with disease and 3-5 months if metastases are present. ELISA. After optimization with the Western Blot assay, the human mesothelin-specific antibodies were mixed with In looking for answers, he found that one reason for the single walled carbon nanotubes and used to coat strips of poor survival rate from pancreatic cancer was the lack of ordinary filter paper.
    [Show full text]
  • Timeline of the Greg and Cathy Griffith Family Foundation
    Timeline of the Greg and Cathy Griffith Family Foundation February 5, 2010 Greg diagnosed with pancreatic cancer Greg and Cathy meet Dr. Moser February 10, 2010 Greg tells Dr. Moser that God is bigger than pancreatic cancer April 2010 Amanda and Luke Ottaway come to the Griffith’s home and ask Greg if they can host a dinner and basketball tournament to raise money for Dr. Moser’s research May 2010 Ellen and Brent Ottaway reach out to the community and host the first Griff’s Run and Gun committee meeting at the Hollidaysburg YMCA August 13, 2010 First Griff’s Run and Gun for a Cure dinner and basketball tournament with speakers Dr. Moser, Dr. Herbert Zeh, and Congressman Bill Shuster Fall 2010 to Spring 2011 Greg’s health improves, and we all experience spiritual growth Greg and Cathy speak at various community events May 11, 2011 Greg’s Whipple operation aborted Greg’s cancer is back Booker Moore and committee present the July 2011 formation of the Greg and Cathy Griffith Family Foundation at the 2nd annual Griff’s Run and Gun for a Cure August 21, 2011 First annual Fund a Cure Night at the Altoona Curve August 26, 2011 Greg passes from pancreatic cancer September 2011 GFF website built Booker Moore and Cathy become founding members of the Alliance of Families Fighting Pancreatic Cancer (AFFPC) April 2012 GFF hosts Movie and a Mission Night, held to recognize Dr. Greg Fulchiero, Sr. Dr. Moser promoted to Co-Executive Director of the new Institute for Hepatobiliary and Pancreatic Surgery at Beth Israel Deaconess Medical Center/Harvard Medical School May 2012 Cathy goes to Phoenix, Arizona to meet pancreatic cancer advocate Kay Kays and TGEN Team Jack Andraka wins Intel Science and Engineer Fair for his early detection of pancreatic cancer July 2012 Jack Andraka speaks at 3rd annual Griff’s Run and Gun for a Cure Jack and Kiera Chirdon meet August 2012 HAHS students, along with teacher Bonnie Waltz, create Tackle Cancer April 5, 2013 GFF, Kaitlin Farnan, and Dr.
    [Show full text]
  • Stylus Magazine Indesign Template
    STRONGERTOGETHER critical values | volume 6 | Issue 4 October 2013 Biobanking Preserving Samples for the Ages p. 6 The Patient Perspective p. 18 Economics of Biobanking p. 32 STRONGERTOGETHER critical values | volume 6 | Issue 4 October 2013 Biobanking Preserving Samples for the Ages p. 6 The Patient Perspective p. 18 Economics of Biobanking p. 32 ASCP Staff Advisers E. Blair Holladay, PhD, SCT(ASCP)CM Executive Vice President Steven F. Ciaccio, CPA, CAE Chief Operating Officer Senior Editor Molly V. Strzelecki Director of Scientific Journals Michelle Hoffman Contributing Editors Sara S. Patterson, MSJ Susan Montgomery, MBA Art Direction and Design Martin Tyminski, MFA Copy Editors Janet Franz Critical Values is published quarterly ©2013 Copyright by the American by the American Society for Clinical Society for Clinical Pathology (ASCP). Pathology, 33 W. Monroe St., Suite Critical Values is published quarterly 1600, Chicago, IL 60603. Postmaster: by the American Society for Clinical send address changes to Critical Pathology, a nonprofit professional Values, American Society for Clinical society with more than 100,000 Pathology 33 W. Monroe St, Ste 1600, members working as pathologists Chicago, IL 60603. and laboratory professionals. Free to members of ASCP, Critical Copies to addresses outside the Values presents news and feature United States and Canada are stories about issues of compelling sent by air. Copies will be replaced without charge if the publisher interest to all members of the receives a request within 60 days of laboratory team. Publication of an the mailing date in the United States article, column, or other item does or within five months in all other not constitute an endorsement by countries.
    [Show full text]